Aflac Incorporated (NYSE: AFL) — A Yen-Levered Cash-Return Machine Repriced From Perpetual Value Stock to Secular Compounder

An independent equity research note Report date: 2026-06-27 Analyst stance: Independent, skeptical, evidence-driven. No recommendation or price target appears in the analysis sections; the single deliberate exception is the labeled Author’s Take block below.

⚡ Author’s Take

This block is the author’s own subjective opinion and general information only — not investment advice. The analysis sections that follow take no position and carry no price target.

Verdict: HOLD / AVOID-at-this-price / accumulate-on-weakness. A genuinely high-quality franchise being priced, for the first time in its history, as a secular compounder — when it is really a low-growth, yen-translated annuity whose per-share growth is ~90% manufactured by buybacks. Great business; wrong price. Directional zone: I’d want to own AFL nearer ~1.5–1.7x adjusted book / ~12–13x adjusted EPS, which maps to roughly $80–95 a share, versus $120.15 today (~2.2x adjusted book, ~16.5x adjusted EPS — the richest multiple in the company’s modern history).

The bull and bear here are not arguing about quality — they agree the franchise is excellent: ~13% GAAP ROE comfortably above cost of capital, a fortress balance sheet (combined RBC ~560%, Japan ESR 227%), and 43 consecutive years of dividend increases. They are arguing about price relative to growth. The uncomfortable fact the 2x-book multiple papers over is that Aflac’s dollar earnings are flat — pretax adjusted earnings were $4,962M in 2025 versus $4,945M in 2024 and $4,310M in 2023 — and the crown-jewel Japan segment’s in-force premium is shrinking (underlying earned premium −1% to −2% a year) because lapses (~¥90bn) exceed even a record sales year (~¥74–80bn). What makes adjusted EPS rise ~mid-single-digits is the relentless retirement of stock: the share count has fallen from 713.7M (2020) to 518.7M (2025), down 27% in five years. That is excellent capital allocation, but it is financial engineering on a static earnings base, and the market is now paying a compounder multiple for it at all-time-high prices. The framing is a crowded low-vol “quality” long (beta 0.36, an unbroken low-volatility grind to record highs) where the multiple has done all the work and the margin of safety is gone. Not a short — you do not short fortress capital, a 2% growing dividend, and a daily buyer of its own stock. But there is no cushion at $120.

Conviction: medium. The single fact that would flip me bullish: a durable inflection in Japan in-force earned premium back to growth (sales sustainably clearing the ~¥90bn lapse hurdle, or the reinsurance franchise scaling into a real second earnings engine), which would justify paying up for growth that is actually there. The single fact that would flip me bearish: a sharp, sustained yen appreciation that craters dollar-translated earnings while the multiple is at a record — the one scenario where this low-vol name is not low-risk.

Tag: “The duck that learned to compound — priced as if it always will.”

📈 Stock Price Action — Five-Year Event Map

Over five years AFL has been one of the steadiest large-cap grinds in the market: from roughly $43 in January 2021 to $120.15 on 2026-06-26 — an all-time closing high, a near-triple with no peak-to-trough drawdown worse than ~14% over the trailing three years (FactorsToday 3-yr max drawdown −13.5%). The stock sits at its 52-week high ($120.15) against a 52-week low of $98.09 (August 2025); it is ~0% off its all-time high. This is the price chart of a low-volatility (beta 0.36) defensive name that the market has steadily re-rated, not a cyclical that round-tripped. The move is a story of multiple expansion stacked on top of buyback-driven EPS — price-to-adjusted-book has roughly doubled from ~1.2x to ~2.2x while dollar earnings stood still.

Cycle narrative. (1)–(2) The base of the move was a value-stock re-rating off pandemic lows — AFL spent 2020–2021 trading below stated book value, a perpetual “cheap insurer.” (3) The 2022–2023 interest-rate shock drove large unrealized losses on Aflac’s available-for-sale bond portfolio into accumulated other comprehensive income (AOCI), which shrank GAAP equity by roughly $10bn and thereby mechanically lifted price-to-book even as the stock rose only modestly — an artifact every reader of the valuation section must hold in mind. (4)–(6) From 2024 onward the dominant driver was factor leadership: in a market rewarding low-volatility, high-quality balance sheets, AFL’s unbroken capital-return record and 0.36 beta attracted a persistent bid, carrying it to ~2.2x adjusted book and an all-time high. The price moves are facts; the attributed drivers are interpretation, cross-referenced to earnings prints, the AOCI disclosures in the 10-K, and the Q1-26 call.

1. Executive Summary

Aflac Incorporated is the dominant supplemental (“third-sector”) health-insurance franchise in Japan and a leading worksite voluntary-benefits insurer in the United States. It is, by almost any quality screen, a very good business: a high-persistency, capital-light insurance model that earns a ~13% return on equity comfortably above its cost of capital, throws off enormous excess capital, and has raised its dividend for 43 consecutive years. Roughly 70% of pretax earnings come from Japan, denominated in yen — a fact that defines both the company’s analytical character and its central risk.

The investment tension is entirely about price versus growth. Aflac’s dollar earnings are flat: pretax adjusted earnings were $4,962M in 2025, essentially unchanged from $4,945M in 2024 and up only modestly from $4,310M in 2023. The Japan segment — the crown jewel — is in gentle run-off at the in-force level: underlying earned premium is declining 1–2% a year because policy lapses (~¥90bn) exceed even a strong sales year (~¥74–80bn). What turns flat dollar earnings into ~mid-single-digit adjusted EPS growth is a relentless buyback: the diluted share count has fallen 27% in five years (713.7M → 518.7M). This is exemplary capital allocation, but it is per-share growth manufactured on a static earnings base.

Despite that, the market has re-rated AFL from a perpetual value stock to a secular compounder. For most of the last decade the shares changed hands at roughly 0.8–1.3x book value and 9–11x earnings; today they trade at ~2.1x GAAP book, ~2.2x adjusted book (ex-AOCI book value per share of $54.06), and ~16.5x adjusted EPS — the richest valuation in the company’s modern history (AZI own-history price-to-book in the 99.98th percentile, composite valuation in the 94th). Part of that P/B optic is an AOCI artifact (rate-driven bond losses shrank the GAAP denominator), but even on the cleaner adjusted-book and earnings measures, the re-rating is real and large.

The franchise quality is not in dispute and the downside is well-protected by fortress capital and a daily corporate buyer of the stock. But at an all-time-high multiple, on flat dollar earnings and a shrinking Japan in-force book, the price embeds an expectation of compounding that the operating fundamentals do not currently supply. The valuation section quantifies what must be true to justify $120; the variant-perception section frames where consensus may be offsides.

2. Business Overview

Aflac Incorporated (founded 1955, headquartered in Columbus, Georgia) sells supplemental health and life insurance through two segments: Aflac Japan and Aflac U.S. The defining characteristic of the franchise is that it does not principally insure the large, capital-intensive “first-sector” (whole life) or “second-sector” (auto/property) risks; its core is “third-sector” products — cancer, medical, accident, hospital indemnity, critical illness, short-term disability, dental/vision — that pay fixed cash benefits directly to the policyholder to offset the out-of-pocket costs of illness and injury that primary health insurance does not cover. These products have attractive economics: they are individually small-premium, high-frequency, high-persistency, and require relatively little capital per dollar of premium because the benefit amounts are capped and defined rather than open-ended.

Aflac Japan (~70% of pretax adjusted earnings; $3,440M of $4,962M in FY2025) is the larger and higher-margin business. Aflac is the number-one seller of cancer and medical insurance in Japan by policies in force, a position it has held for decades after pioneering cancer insurance there in 1974. It distributes through a broad network: traditional agencies, affiliated corporate agencies, alliance partners, and — importantly — banks and a long-standing alliance with Japan Post. Japan’s segment pretax margin is ~35%. Within Japan, products span the third-sector core (cancer: “Miraito”; medical: “Onsen Tallett”/new medical; nursing care; income support) plus a first-sector savings block (WAYS, child endowment) that is now largely in run-off.

Aflac U.S. (~29% of pretax adjusted earnings; $1,421M) sells voluntary worksite benefits — accident, disability, critical illness, hospital indemnity, dental, vision, life, and a growing group/voluntary book — primarily through payroll deduction at employers, sold by an agent force (~10,000–11,000 recruited annually) plus brokers and group channels. The U.S. segment pretax margin is ~20%. Growth here is bifurcated: group and consumer-markets products grew ~12.4% in Q1-26 while the legacy individual agent channel is flat-to-down.

A third, emerging leg — reinsurance. Through Aflac Re Bermuda, the company has begun assuming third-party blocks of Japanese liabilities (a whole-life annuity block from Japan Post Insurance was assumed in Q1-26). Management frames this as capital-light, immediately accretive, and potentially “material over time,” using Aflac’s AA-rated balance sheet as the competitive asset.

How it makes money. Like any insurer, Aflac earns an underwriting margin (premiums collected less benefits paid and expenses) plus a spread on the float — the ~$110bn investment portfolio backing policy reserves. Revenue is overwhelmingly recurring: renewal premium on a large, sticky in-force block (Japan persistency 92.8%, U.S. 79.3%). Total revenues were ~$17.4bn in FY2025 (down ~9% year-over-year, largely a yen-translation and reinsurance-cession optic rather than an underlying collapse). The economic engine is the durability and capital-efficiency of the in-force book, not top-line growth.

Verdict: A simple, understandable, recurring-revenue insurance model with a genuinely dominant position in its core Japanese niche — but one whose largest profit pool is mature and whose reported revenue is heavily mediated by the yen.

3. Industry Dynamics

Aflac operates in two very different insurance markets joined by a common product philosophy (supplemental/voluntary protection).

Japan third-sector insurance is the structurally more attractive of the two — and the more challenged for growth. Japan is the world’s third-largest insurance market, with a deeply ingrained culture of insurance ownership and exceptionally high persistency. The third sector (cancer/medical) is a defined niche in which a handful of players (Aflac, Dai-ichi, Tokio Marine’s affiliates, MetLife Japan, Japan Post’s distribution) compete, and Aflac’s scale and brand give it the leading share. The attractiveness: high renewal persistency, rational competition, a large installed base, and rising consumer anxiety about out-of-pocket medical costs as Japan’s universal health system shoulders an aging population. The structural problem is demographics and saturation. Japan’s population is shrinking and aging; the third-sector market is mature; and Aflac’s own in-force premium is in gentle decline because new sales, even after a successful 2024–2025 marketing transformation that drove Q1-26 sales +25.5%, cannot yet replace the natural lapsation and paid-up roll-off of a vast legacy book (~¥90bn annual run-off versus ~¥74–80bn sales). This is a profit pool you can defend and milk superbly; it is not one that grows on its own. In Marathon “capital cycle” terms, this is a low-supply-growth, rational-oligopoly niche where incumbents earn good returns precisely because no one is pouring capital in to grow a shrinking pie — favorable for returns, unfavorable for volume.

U.S. voluntary/supplemental benefits is structurally more competitive and more crowded. The worksite voluntary market is fragmented and contested by Unum (and its Colonial Life unit), Globe Life, MetLife, Guardian, Cigna/New York Life, Allstate’s voluntary unit, and others. Switching costs at the employer level exist (incumbency on the payroll platform, enrollment relationships) but are far lower than in Japan, and the product is more commoditized. The secular trend — rising U.S. out-of-pocket healthcare costs and high-deductible plan proliferation — is a genuine tailwind for demand for supplemental products, but it is a tailwind every competitor enjoys. Growth is shifting toward group/voluntary sold to small employers (sub-100 lives), where Aflac is investing, and away from the legacy individual agent model.

Regulation. Japan’s FSA regulates capital via the economic solvency ratio (ESR) regime; Aflac’s ESR of 227% (243% with the undertaking-specific parameter) is very strong. U.S. statutory capital is governed by RBC (combined ~560%, far above any action level). The principal regulatory friction is at the U.S. state level — occasional rate-cut pressure on specific products (one such headline in mid-2026 was addressed as immaterial and not spreading) — and the perennial overhang of any change to Japan’s national health system that would alter demand for supplemental cover.

Verdict: A genuinely good core industry (Japan third-sector: rational, high-persistency, high-margin) wrapped around a mature-to-shrinking demographic backdrop, plus a structurally average and more competitive U.S. voluntary market with a real demand tailwind. Good for returns and durability; poor for organic volume growth.

4. Competitive Position

Aflac’s moat is real, nameable, and — crucially — strongest exactly where the market is most mature.

In Greenwald’s taxonomy, Aflac Japan combines two of the three genuine advantage types: customer captivity (demand-side) and economies of scale within a defined niche.

• Customer captivity / habit and persistency. A 92.8% Japanese persistency rate is the financial fingerprint of captivity: policyholders renew year after year, premiums compound on an installed base, and the cost of re-acquiring a customer is avoided. Cancer/medical insurance in Japan is a multi-decade, low-premium, “set-and-forget” product purchased once and rarely re-shopped; the recent uptick in “lapse and reissue” (policyholders upgrading to newer products) is itself evidence of captivity — they stay with Aflac and trade up rather than leave. This captivity is the moat’s beating heart, and it shows up directly in the ~35% Japan pretax margin and the ROE.
• Scale economies in a niche. As the #1 cancer/medical insurer, Aflac spreads fixed costs (the iconic “Aflac duck” brand — one of the most recognized in Japan — distribution infrastructure, the Japan Post and bank alliances, claims systems) across the largest in-force base in the category. A subscale entrant cannot replicate the brand or the distribution reach at competitive unit cost. The expense ratio in Japan (~19.5%) reflects this.
• Brand. The duck is a genuine intangible asset in both markets; brand matters in insurance because it substitutes for trust in an intangible promise-to-pay. It is strongest in Japan and meaningful, if less dominant, in the U.S.

Aflac U.S. has a weaker moat — narrow switching costs and brand, in a contested market. The worksite incumbency (being the installed voluntary carrier on an employer’s payroll platform) creates some stickiness, and the brand carries weight, but persistency is markedly lower (79.3%) and the competitive set is deep. This is closer to a “good operator in an average industry” than a structural fortress.

The moat passes the financial test — but the test it fails is growth. The right way to validate a moat (per the playbook) is to ask whether a financial outcome would deteriorate without it. Strip out Aflac’s Japanese persistency and brand and the ~35% segment margin and 13% ROE collapse — so the moat is real. But a moat’s value is moat × growth, and here growth is the missing factor: the franchise defends a shrinking in-force pool. Market-share stability — Greenwald’s key test — is high (Aflac’s share of Japanese cancer insurance has been durable for decades), which confirms the moat; but a stable share of a flat-to-declining market produces durable returns without compounding volume.

Verdict: A durable, correctly-identified moat (captivity + niche scale + brand) in Japan, and a narrower one in the U.S. — genuine and defensible, but attached to a mature/declining revenue base. The competitive advantage protects the return, not the growth.

5. Growth History and Forward Opportunities

History (the honest version): per-share growth, not enterprise growth. Over 2020–2025, total revenue fell from ~$22.3bn to ~$17.4bn (a mix of yen weakness, the run-off of the first-sector savings block, and internal reinsurance cessions), and pretax adjusted earnings were essentially flat ($4.3–5.0bn across the period). Yet adjusted EPS rose at a mid-single-digit pace and the stock nearly tripled. The reconciliation is entirely the share count: 713.7M (2020) → 652.1M (2021) → 615.3M (2022) → 578.5M (2023) → 550.0M (2024) → 518.7M (2025). Aflac retired 27% of its shares in five years. This is high-quality capital allocation, but it is not business growth — it is the conversion of a static earnings stream into a rising per-share number.

Segment growth detail:

• Japan pretax adjusted earnings: $3,234M (2023) → $3,494M (2024) → $3,440M (2023→25 roughly flat in dollars, with yen translation a headwind). Underlying earned premium is declining 1–2% a year. The 2024–2025 marketing-and-sales transformation is a genuine bright spot — Q1-26 sales rose 25.5%, led by the new cancer (“Miraito”) and medical products, with all distribution channels up — but management is explicit that sales must reach ~¥90bn to merely stabilize in-force premium, against guidance of ~¥74–80bn for 2026. So even a good year shrinks the book, just more slowly.
• U.S. pretax adjusted earnings: $1,501M (2023) → $1,419M (2024) → $1,421M (2025), flat-to-slightly-down. Net earned premium is growing modestly (+3.5% in Q1-26) on improving persistency (79.3%) and group momentum (+12.4%), offset by a flat-to-declining individual agent channel. This is the segment with the clearer organic growth path, but off a smaller, lower-margin base.

Forward opportunities (ranked by plausibility):

1. Reinsurance (Aflac Re Bermuda). The most credible new growth lever — capital-light, immediately accretive, leveraging the AA balance sheet to assume Japanese blocks (Japan Post annuities the first deal). Management says it could become “material over time,” though the first transaction was small and near-term dilutive (a few million dollars of negative earnings impact for a few quarters before turning accretive). This is the bull’s best argument for a real second earnings engine; it is unproven at scale.
2. U.S. group/voluntary expansion into small-employer and consumer-direct channels (the “buy the bill” investments), growing ~25% in aggregate but off a small base.
3. Japan sales sustaining above the ~¥90bn lapse hurdle — the only path to organic in-force growth, not yet in hand.
4. Yen normalization — not a business opportunity but a translation tailwind that would flatter reported dollar growth if/when the yen strengthens (a double-edged factor, see Risks).

Verdict: low-quality growth at the enterprise level, high-quality engineering at the per-share level. The growth that has driven the stock is financial (buybacks), not operational. The operational growth that does exist (U.S. group, reinsurance optionality) is real but small relative to the $5bn earnings base. An investor paying a compounder multiple is paying for compounding that the franchise, today, does not organically produce.

6. Financial Quality

Profitability and returns. Aflac earns a GAAP ROE of 13.1% (FY2025) — comfortably above a cost of equity I’d peg around 8–9% for a low-beta insurer — and an adjusted ROE management cites at ~12.8% (16.4% excluding foreign-currency remeasurement). These are good, durable returns. Data note (important): third-party aggregator ROIC.ai reports an ROE of ~6.8% and a price-to-book of ~1.07x for AFL; both are wrong, the artifact of a doubled book-value figure in their dataset (~$103/share vs. the true ~$57). The 10-K is authoritative: total shareholders’ equity was $29,490M at FY2025, book value per share ~$56.85, and GAAP ROE 13.1%. Every return and book multiple in this memo uses the filing, not the aggregator.

Earnings quality and the GAAP/adjusted gap. Aflac’s GAAP net earnings are genuinely volatile and not a clean read on the business: FY2025 net earnings were $3,646M (diluted EPS $6.82) versus $5,443M ($9.63) in FY2024 — a 33% drop that reflects not an operating collapse but swings in net investment gains/losses, derivative/hedge marks, and the new long-duration (LDTI) reserve and market-risk-benefit remeasurement, plus FX. The cleaner operating read is pretax adjusted earnings, which were essentially flat at $4,962M / $4,945M / $4,310M (2025/24/23). Management’s adjusted EPS — which excludes investment gains/losses and amortizes the FX impact — runs ~$7.2–7.3 for 2025 and grew ~6.6% ex-FX in Q1-26. The discipline for any analyst: use adjusted pretax earnings and adjusted EPS for the operating story, and GAAP equity (with AOCI understood) for the balance-sheet story; do not anchor on headline GAAP net income, which the yen and rate marks whipsaw.

Margins. Segment pretax margins are strong and stable: Japan ~35%, U.S. ~20%. Benefit ratios are well-controlled and running favorable to plan (Japan 62.9% in Q1-26, within the 60–63% guide; U.S. 47.2%, near the low end of the 42–52% guide), helped by favorable reserve remeasurement gains and benign claims in cancer, hospitalization, and group disability.

Balance sheet and investments. The ~$110bn investment portfolio is the engine of float income. It is conservatively positioned overall (predominantly investment-grade fixed income, much of it dollar-denominated to support the yen-hedging program) but carries the usual insurer tail risks: a commercial-real-estate and middle-market-loan sleeve that has produced modest, manageable impairments (Q1-26: $24M of real-estate-owned impairments, $19M of loan charge-offs — small relative to earnings), and large AOCI swings on the AFS book as rates move (the AOCI position swung from a −$5.5bn drag in 2023 toward roughly flat/positive by 2025, the mechanical driver of the P/B optic discussed in the relevant section). Capital is a genuine fortress: combined RBC ~560%, Japan ESR 227% (243% with USP), holdco unencumbered liquidity $3.4bn ($2.4bn above the $1bn minimum), adjusted leverage 21.2% within a 20–25% target. ~65% of debt is yen-denominated as an intentional economic hedge of the yen value of Aflac Japan.

Cash generation. As an insurer, “free cash flow” is best read as distributable capital generation to the holding company, which funds dividends and buybacks. Aflac returned $1.3bn in Q1-26 alone ($1.0bn buyback + $0.315bn dividends) and ~$4–5bn annually — a level it has sustained for years and which the capital ratios comfortably support. Reported operating cash flow (~$2.5bn in 2025) understates this because of insurance-accounting timing; the capital-return run-rate is the truer measure of cash power.

Verdict: economics are high-quality and durable, but they do not improve with scale because there is no scale being added — margins, returns, and benefit ratios are excellent and stable, capital is abundant, and the chief earnings-quality caveat is interpretive (use adjusted, not GAAP) rather than a red flag. This is a financially pristine, low-growth compounder of per-share value.

7. Capital Allocation

Capital allocation is Aflac’s single most impressive attribute and the proximate cause of the entire equity story — which makes it the right place to be most skeptical about price.

Dividends. Aflac has raised its dividend for 43 consecutive years, a record matched by very few companies in any sector and treasured by management as a signal. The payout ratio is conservative (~33% of GAAP earnings, lower on adjusted), leaving ample room for continuation. The yield is ~2.0% at $120. This is exemplary, shareholder-friendly, and clearly sustainable given the capital position.

Buybacks — the engine, and the question. The repurchase program is enormous and consistent: 33.0M shares for ~$3.5bn in 2025, 30.4M for $2.8bn in 2024, and a fresh 100M-share authorization on top. The cumulative effect — 27% of shares retired in five years — is the entire source of per-share earnings growth. The skeptical point: Aflac is buying back stock at all-time-high prices and ~2.2x adjusted book, versus a decade in which it often bought below book. The IRR on repurchasing your own ~13%-ROE equity at ~1x book is excellent; at ~2.2x book it is materially lower (you are paying ~2.2x for a ~13% return on the underlying equity, i.e., capitalizing it at a ~6% earnings yield). Management explicitly frames buybacks as offering “good relative IRR,” and to be fair, an insurer drowning in excess capital with no high-return organic outlet has few better uses — but investors should recognize that the capital-return machine is now deploying cash at progressively richer prices, which lowers the future per-share compounding it can manufacture. This is the pro-cyclical edge of an otherwise admirable program.

M&A and reinsurance. Aflac has been disciplined-to-absent on large acquisitions, preferring buybacks — a point in its favor given the industry’s M&A graveyard. The new reinsurance strategy (Aflac Re) is a measured, “evolution not revolution” (Amos’s words) deployment of the balance sheet that consumes some capital but, management insists, not enough to alter the shareholder-return cadence. Watch it for both upside (a real second engine) and risk (assuming longevity/spread risk onto a clean balance sheet).

Incentive alignment. Executive compensation has historically been tied to adjusted EPS and adjusted ROE excluding foreign currency (AROE) — sensible, business-aligned metrics — alongside RBC/solvency. Caveat: the comp framework (per the available proxy) does not appear to feature a return-on-invested-capital or economic-value metric, and adjusted-EPS-linked pay can reward buyback-driven per-share growth that is not matched by enterprise value creation — precisely the dynamic at work here. CEO Daniel Amos has led the company since 1990; the Amos family are the founders and long-tenured stewards (a meaningful but non-controlling stake; no dual-class structure), which has produced remarkable continuity and a genuine owner-operator culture, but also the governance questions that attend a three-decade CEO tenure.

Verdict: among the best capital-return programs in the insurance industry — disciplined on M&A, generous and sustainable on dividends, aggressive on buybacks — but now executing into a record valuation, which is steadily eroding the per-share value the buyback can create. Management has allocated capital intelligently; the open question is whether buying ever-richer stock remains intelligent at 2.2x book.

8. Changes and Headwinds — Last Two Years

Strategic and operational changes:

• Japan marketing-and-sales transformation (2024–2026). A deliberate overhaul of Aflac Japan’s marketing and distribution drove a sharp sales re-acceleration — Q1-26 sales +25.5%, with new products (Miraito cancer, new medical) leading and all channels growing. This is the most important positive operational change, though it has not yet flipped in-force premium to growth.
• Launch of the Aflac Re Bermuda reinsurance franchise (2025–2026), with the first external/Japan Post block assumed in Q1-26 — a new, capital-light growth and earnings-diversification avenue, small today.
• Continued run-off of the legacy first-sector savings block and ongoing internal reinsurance restructuring (which depresses reported net earned premium without harming economics).
• Adoption of LDTI / new long-duration GAAP, which has materially increased the period-to-period volatility of GAAP net earnings (reserve remeasurement, market-risk benefits) and is the chief reason headline EPS now swings far more than the underlying business.

Headwinds:

• The yen. The yen weakened to ~149–151/dollar (from ~140 in 2023), a persistent translation drag on dollar-reported Japanese earnings and revenue. The enterprise FX hedge (yen-denominated debt, dollar-asset matching) protects economic value and capital, but reported dollar earnings still feel the translation.
• Shrinking Japan in-force premium (the structural headwind, detailed above).
• U.S. state rate-cut pressure on specific products — a mid-2026 regulatory headline that management characterized as immaterial and not spreading, but a reminder of the regulatory friction in the U.S. book.
• Commercial real estate — modest, ongoing impairments in the CRE/middle-market loan sleeve, manageable relative to earnings but a watch item through the cycle.
• Valuation itself — the most underappreciated headwind. Each incremental buyback at ~2.2x book and each tick of multiple expansion raises the bar for future returns.

Verdict: The two-year changes are a mix that nets to neutral-to-slightly-positive operationally (Japan sales transformation and reinsurance optionality are genuine positives; yen drag and in-force decline are genuine negatives) — but they do not justify the simultaneous doubling of the valuation multiple. The fundamentals improved at the margin; the price improved at the core.

9. Risk Analysis (Risk Matrix)

The dominant risks are valuation and yen — and they are correlated in the bear case (a yen rally that dents earnings while the multiple is at a record). The franchise/solvency risks are low; this is not a balance-sheet-fragility story.

10. Valuation Discussion (Embedded Expectations)

Where the multiple sits. At $120.15, against ~518.7M shares, Aflac’s market capitalization is ~$60–62bn. The key multiples:

• Price / GAAP book (equity $29.49bn): ~2.1x.
• Price / adjusted book ex-AOCI (BVPS $54.06): ~2.2x.
• Price / adjusted EPS (~$7.2–7.3): ~16.5x. Price / GAAP diluted EPS ($6.82): ~17.6x.
• Dividend yield: ~2.0%.
• AZI own-history percentiles: P/B 99.98th, P/S 96.5th, P/E 87.0th, composite 94.5th — i.e., at or near the richest the stock has ever been on every standard measure.

(Note on EV multiples: enterprise value is not a meaningful metric for a life/health insurer — the investment portfolio is the operating asset, not “cash” — and aggregator EV figures for AFL are nonsensical (deeply negative). Valuation is correctly anchored on P/E and P/B, as above.)

The AOCI caveat — read the P/B honestly. The single most-cited “richest ever” figure, the 99.98th-percentile P/B, is partly an accounting artifact. The 2022–2023 rate shock pushed large unrealized losses on Aflac’s AFS bond portfolio into AOCI, shrinking GAAP equity by roughly $10bn relative to where amortized cost would put it. Those losses are economic but largely unrealized on assets held to back long-duration liabilities; book value understates the through-cycle equity. The cleaner denominator is adjusted book ex-AOCI ($54.06/share), on which the stock trades ~2.2x — still the richest in its modern history, but not the near-infinite percentile the raw P/B implies. The point stands either way; it is just less extreme than the headline.

Embedded-expectations / reverse-DCF logic. What must be true to justify $120?

• A ~2.0% dividend yield plus the company’s own ~5–6% adjusted-EPS growth (mostly buyback) implies a ~7–8% forward total return if the multiple holds — adequate but unexciting for a no-organic-growth business, and entirely dependent on the multiple not reverting.
• To earn a compounder’s return from here (low double digits), one of two things must happen: (a) the multiple expands further (already at record highs — a stretch), or (b) the underlying earnings growth re-accelerates — which requires Japan in-force to inflect to growth and/or reinsurance to scale into a real second engine. Neither is in hand.
• Put differently, the market is capitalizing a flat-dollar-earnings, shrinking-in-force franchise at ~16.5x adjusted earnings and ~2.2x book — multiples historically reserved for genuine organic compounders. The price embeds the assumption that Aflac has become a compounder, when the operating evidence says it is a superb capital-return vehicle on a static base.

Scenario sketch (illustrative, not a target):

• Bear (multiple reverts toward historical ~1.4–1.6x adj book / ~11–12x adj EPS as the market re-recognizes the no-growth reality, or a yen rally dents earnings): a price zone materially below current — roughly the high-$70s to low-$90s.
• Base (the franchise holds, buybacks continue, multiple drifts modestly lower from record levels toward ~1.8–2.0x adj book; total return ≈ dividend + buyback-EPS growth minus mild de-rating): roughly flat-to-modestly-higher, low-to-mid $100s to ~$120s.
• Bull (Japan in-force inflects to growth and/or reinsurance scales, justifying the premium; multiple sustained or expands): mid-$130s+.

The asymmetry at $120 favors the downside: the base case is “you collect a ~2% dividend and modest buyback growth for a fully-priced total return,” and the bear case is a real de-rating, while the bull requires an operational inflection not yet visible.

Verdict: priced for compounding the franchise does not organically deliver. On every own-history measure AFL is at or near its richest valuation ever; the cleaner adjusted-book lens tempers but does not overturn that conclusion. There is no margin of safety at the current multiple. (No price target; no recommendation — see the Author’s Take for the subjective view.)

11. Variant Perception

Consensus view. Aflac is a blue-chip, low-volatility, defensive “sleep-well-at-night” insurer: 43 years of dividend growth, fortress capital, a dominant Japanese franchise, ~13% ROE, and a management team that returns prodigious cash. In a market rewarding quality and low beta, it deserves to compound steadily — and the factor data confirm the market treats it exactly so (beta 0.36; FactorsToday loads it primarily on the Insurance-industry and LowVolatility factors with positive alpha; a 3-year Sharpe above 1.1 with a max drawdown of just −13.5%; an unbroken grind to all-time highs). The tape is a textbook crowded low-vol “quality” long.

The strongest bull case. Quality plus capital return is its own reward: a ~13% ROE business with a fortress balance sheet, buying back 5–6% of its stock a year, raising the dividend annually, with optionality on top from (a) Japan sales re-accelerating past the in-force stabilization hurdle after the marketing transformation, (b) the reinsurance franchise scaling into a material second earnings engine, and © a yen normalization that would flatter dollar earnings. In that world, the premium multiple is justified and even cheap.

The strongest bear case. You are paying the richest multiple in the company’s history (~2.2x adjusted book, ~16.5x adjusted earnings, vs a decade at ~1.2x / ~10x) for a business whose dollar earnings are flat and whose core Japanese franchise is in gentle run-off. The entire equity return of the last five years has been multiple expansion plus buyback-manufactured EPS on a static earnings base — and the buyback is now being executed at ever-richer prices, lowering the per-share value it can create. The re-rating from “perpetual value stock at sub-book” to “secular compounder at 2x book” was a sentiment/factor event, not an earnings event, and it can reverse. The yen — the one factor that makes this “low-risk” name genuinely risky — is the catalyst that could expose the no-growth reality.

The 3–5 assumptions that matter most:

1. Will Japan in-force premium inflect to growth? (Bull needs yes; today it is −1% to −2%.) — The single most important swing variable.
2. Does the premium multiple hold, or revert? (Bull needs it to hold; it is at all-time highs.)
3. Does the yen strengthen materially? (Hurts reported earnings; helps long-term if it reflects a stronger Japan — but near-term a clear negative to the bull at a record multiple.)
4. Does reinsurance (Aflac Re) become a real, accretive earnings engine, or stay a rounding error?
5. Does management keep buying back stock at 2.2x book, and is that still value-accretive?

What would falsify each side. Falsifies the bull: two-to-three more years of declining Japan in-force premium and flat dollar earnings while the multiple sits at records — confirming a no-growth franchise being overpaid for — or a sharp yen rally that cuts reported EPS. Falsifies the bear: Japan sales sustainably clearing ~¥90bn and in-force premium turning positive, and/or reinsurance scaling to a meaningful share of earnings — converting the per-share story from financial engineering into genuine compounding and validating the premium.

Variant conclusion: Consensus is right about the quality and wrong, or at least complacent, about the price embedded in a no-growth franchise. The factor-positioning read (a crowded, fully-valued low-vol long at all-time highs) is consistent with a name where the easy re-rating money has been made and the forward return is a fully-priced ~2% yield plus modest buyback growth — unless the operational inflection the bull needs actually arrives.

12. Fact vs. Interpretation Table

13. Open Questions

1. What is the precise 2026 adjusted-EPS trajectory net of FX, and how much is organic versus buyback? (Q1-26 +6.6% ex-FX is encouraging but small-sample.)
2. Can Japan sales sustainably reach ~¥90bn to stabilize in-force premium, or does the marketing-transformation lift fade after the new-product launch cycle?
3. How large and how accretive can Aflac Re realistically become — a genuine second engine or a capital-consuming sideline? What is the target ROE on assumed blocks?
4. What is the current Amos-family / insider ownership and the latest comp design — does the incentive plan now include any capital-efficiency (ROIC/EV) metric, or only adjusted EPS/AROE? (Latest saved proxy is dated; needs the current DEF 14A.)
5. Insider transaction pattern — are there any open-market purchases, or only routine grants/sales? (Form 4 corpus listed-only in this pull; warrants a direct read.)
6. Through-cycle CRE/middle-market loan exposure — what is the size, LTV, and maturity wall of the sleeve generating the recurring small impairments?
7. How does management think about buyback discipline at 2.2x book — is there a valuation level at which it would prefer to hold capital or accelerate reinsurance/M&A instead?

14. What Must Be True (Bull and Bear, with Falsification Tests)

For the BULL case to be right (AFL compounds from $120 and the premium multiple is justified):

• Japan must stop shrinking: in-force earned premium inflects from −1/−2% toward flat-to-positive as sales sustain above ~¥90bn — and/or Aflac Re scales into a materially accretive second earnings engine.
• Dollar adjusted earnings must move from flat to growing (mid-single-digit organic, not just buyback), validating the compounder multiple.
• The yen must not appreciate sharply against a record multiple.
• Falsification test: if, by FY2027–2028, Japan in-force premium is still declining and pretax adjusted dollar earnings are still ~flat (~$5bn) while the stock holds a ~16x+/~2x-book multiple, the bull thesis is falsified — the market is overpaying for engineered per-share growth and a de-rating is the likely resolution.

For the BEAR case to be right (AFL de-rates / underperforms from $120):

• The premium multiple must revert toward the franchise’s no-organic-growth reality (toward ~1.5–1.8x adjusted book / ~11–13x adjusted EPS), or a yen rally must cut reported dollar earnings while the multiple is rich.
• Buybacks at ~2.2x book must prove value-dilutive enough, against flat earnings, that per-share compounding slows visibly.
• Falsification test: if Japan sales durably clear ~¥90bn and in-force premium turns positive, and reinsurance contributes a growing, accretive earnings stream, the bear thesis is falsified — Aflac would have become the organic compounder the multiple already pays for, and the premium would be justified rather than vulnerable.

The crux that decides both: Is Aflac a compounder, or a superb capital-return vehicle on a static, yen-translated, gently-shrinking base? The price says the former; the operating evidence today says the latter. Resolving that — via the Japan in-force inflection and the reinsurance build — is the whole game.

15. Source Appendix

See the separate Source Appendix (Appendix B in the combined report) for the full, dated source list. Primary sources: Aflac Incorporated FY2025 Form 10-K (filed 2026-02-25, CIK 0000004977); Q1-26 earnings call transcript (2026-04-30); the trailing 60-month SEC corpus (10-K/10-Q/8-K/DEF 14A); ROIC.ai fundamentals and ratios (reconciled to filings, with the noted book-value data error); AZI own-history valuation percentiles and news feed (2026-06-26); AZI 5-year price history; FactorsToday factor/risk model (2026-06-26).

APPENDIX A — Standard Diligence Questionnaire

Aflac Incorporated (NYSE: AFL) — as of 2026-06-27

Supplemental to the research memo. Answers are grounded in primary sources, labeled Fact / Interpretation / Assumption where it matters. Where a question does not map to a life/health insurer, the correct sector analog is given.

General

What thoughtful questions have other investors asked about this company? The recurring institutional questions (from the Q1-26 call) cluster on: (1) excess capital — “you have so much excess capital, what will you do with it?” was explicitly the #1 question; (2) the reinsurance strategy (Aflac Re) — is it a sign the core has run out of growth, and how big/accretive can it get; (3) the Japan in-force premium puzzle — why strong sales have not yet translated into earned-premium growth; (4) U.S. benefit-ratio sustainability after a favorable quarter; and (5) leverage/yen interaction. The buy-side debate, properly framed, is not about quality but about whether a no-organic-growth franchise should trade at a record multiple.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: Neither cyclically high nor low in an operating sense — Aflac’s underwriting earnings are remarkably stable (not cyclical like a P&C insurer). However, GAAP net earnings are artificially volatile due to investment gains/losses and FX/LDTI remeasurement (FY25 GAAP NI $3,646M vs FY24 $5,443M is an accounting swing, not an operating one). The cleaner pretax adjusted earnings are flat-at-a-plateau (~$4.9–5.0bn). One could argue earnings are modestly yen-depressed (a weak yen is translating Japan’s ~70% earnings share lower).

Driven by the external environment or internal actions? Both: internal (buybacks driving per-share growth; the Japan marketing transformation) and external (the yen, which moves ~70% of earnings on translation; interest rates moving investment income and AOCI).

How stable are revenues? Highly stable at the premium level (persistency 92.8% Japan / 79.3% U.S.), but reported revenue is declining (~$22bn → ~$17bn over five years) on yen translation, savings-block run-off, and reinsurance cessions. Renewal premium is among the stickiest revenue streams in any industry.

Outlook for products/services? Stable demand (rising out-of-pocket medical costs in both markets support supplemental products), but a mature-to-declining Japanese volume base and a modestly growing U.S. group/voluntary base.

How big will this market be — growing, shrinking, domestic or international? Japan third-sector: large but mature/shrinking with demographics. U.S. voluntary: growing modestly, more competitive. ~70% international (Japan), ~30% domestic (U.S.).

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Japan: stable, rational oligopoly (less competitive in a good way — share has been durable for decades). U.S.: persistently competitive and fragmented (Unum/Colonial, Globe Life, MetLife, Guardian).

How profitable is the business (ROIC, ROE)? GAAP ROE 13.1% (FY25), adjusted ROE ~12.8% (16.4% ex-FX) — comfortably above an ~8–9% cost of equity. Sector-analog note: ROIC is not the standard metric for an insurer (capital is regulatory, not invested-capital, driven); ROE and ROE-ex-FX are the right gauges, and Aflac’s clear the cost of capital. Data caveat: third-party ROIC.ai shows ~6.8% ROE — an error from a doubled book-value figure; the 10-K’s 13.1% is authoritative.

How profitable is the industry — competitors, barriers to entry? Japan third-sector is high-margin (Aflac ~35% pretax) with high barriers (brand, scale, distribution alliances, persistency). U.S. voluntary is lower-margin (~20%) with lower barriers.

Can the business be easily understood? Yes — a supplemental insurer earning underwriting margin plus investment spread on a sticky in-force book. The complexity is in the accounting (LDTI, FX, AOCI), not the business.

Can it be undermined by foreign low-cost labor? No — insurance is a domestic regulated, distribution- and brand-driven business; not labor-arbitrage exposed.

Do brands matter? Yes, materially. The “Aflac duck” is among the most recognized brands in Japan and well-known in the U.S.; brand substitutes for trust in an intangible promise-to-pay. This is one of the moat’s three pillars.

What is the nature of competition? Distribution reach, brand, product innovation (new cancer/medical products), pricing/persistency, and — increasingly in Japan — bancassurance and alliance access (Japan Post).

Customers’ switching costs? High in Japan (habit, multi-decade products, 92.8% persistency); lower in the U.S. (79.3% persistency; worksite incumbency provides some stickiness).

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Interpretation: The value of the in-force book and the brand are not on the balance sheet at economic value. Conversely, AOCI understates equity by ~$10bn versus amortized cost (unrealized AFS bond losses on assets backing long liabilities) — economic but largely unrealized.

Off-balance-sheet liabilities? Standard insurance reserves are on balance sheet; the principal “hidden” exposures are mass-lapse risk (a capital charge that rises with yen rates), longevity/spread risk being added via Aflac Re, and the FX exposure managed by the enterprise hedge.

How conservative is the accounting? Reserving appears conservative (favorable remeasurement gains running ahead of plan in both segments). LDTI has increased volatility but not aggressiveness. Adjusted metrics are clearly disclosed and reconciled.

How CapEx-hungry is the business? Minimal physical CapEx (it is an insurer). The relevant “capital intensity” is regulatory capital per dollar of premium, which is low for third-sector products — a structural attraction.

Capital Allocation & Management

How much FCF does the business generate, and how is it used? Read as distributable capital generation: ~$4–5bn/year returned to shareholders (Q1-26 alone: $1.0bn buyback + $0.315bn dividends = $1.3bn). Philosophy: fund the dividend (43 straight years of increases, ~33% payout), then buy back stock aggressively, with reinsurance/M&A a measured supplement.

Significant acquisitions recently? No large M&A — a positive discipline. The new development is reinsurance (Aflac Re assuming Japanese blocks, first deal Q1-26), a measured, capital-light avenue.

Buying back shares? Yes, heavily — 27% of shares retired 2020–2025; 100M-share fresh authorization. Caveat: now executed at ~2.2x book / all-time highs, a lower-IRR deployment than the sub-book buybacks of prior years.

Issuing large amounts of new shares to insiders? No material dilution; the share count falls steadily. SBC is immaterial relative to the buyback.

Compensation policy of directors/management? Historically tied to adjusted EPS and adjusted ROE ex-FX (AROE) plus RBC/solvency — business-aligned, but no apparent capital-efficiency/ROIC metric, and adjusted-EPS-linked pay can reward buyback-driven per-share growth on flat enterprise earnings. Open item: latest proxy needed to confirm current design.

Motivations of management? Founder-family stewardship (Amos family; Daniel Amos CEO since 1990) — strong owner-operator continuity and a treasured dividend record, balanced against the entrenchment/succession questions of a 36-year CEO tenure. No dual-class structure.

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? No — Aflac Incorporated is a U.S.-domiciled common stock (Georgia HQ), NYSE-listed, files standard 10-K/10-Q. (Its largest operations are in Japan, but the parent is a U.S. filer; no K-1, no ADR.)

Dividend policy? ~2.0% yield; ~33% payout; 43 consecutive years of increases — a core part of the equity identity and clearly sustainable on the capital position.

How profitable is the business? Very — ~13% ROE, ~35%/~20% Japan/U.S. pretax margins, strong and stable.

Is net income diverging from cash from operations? Yes, but for benign insurance-accounting reasons. GAAP NI ($3.6bn FY25) is whipsawed by investment/FX marks; operating cash flow (~$2.5bn) is depressed by insurance timing; the truest cash gauge is the ~$4–5bn of distributable capital actually returned. Watch the GAAP-vs-adjusted gap as a signal-quality issue, not a fraud flag.

Risks & Downside

What factors would cause the stock to decline? (1) A valuation de-rating from record-high multiples; (2) a sharp yen appreciation cutting reported dollar earnings; (3) continued Japan in-force shrinkage eroding the earnings base; (4) a credit/CRE shock in the investment portfolio; (5) a U.S. competitive/regulatory setback.

Risk of a catastrophic loss? Low — fortress capital (RBC ~560%, ESR 227%), a diversified investment-grade portfolio, and a low-tail third-sector underwriting book.

Chance of a total loss? Remote. This is a balance-sheet-strong, cash-generative franchise; the realistic risk is underperformance from a rich price, not impairment.

Recent News & Events

Has the business environment changed recently? Modestly: (1) Japan’s 2024–2026 marketing transformation drove Q1-26 sales +25.5%; (2) the launch of the Aflac Re reinsurance franchise (Japan Post block, Q1-26); (3) persistent yen weakness (~149–151/$); (4) a transient U.S. state rate-cut headline (mid-26, characterized as immaterial). The news tape is otherwise quiet — appropriate for a low-volatility defensive name.

Significant acquisitions? None of scale; the reinsurance assumption is the notable transaction.

Change in accounting policies? The adoption of LDTI / new long-duration GAAP has materially increased GAAP earnings volatility (reserve remeasurement, market-risk benefits) — the chief reason headline EPS now swings far more than the underlying business.

Recent changes — new markets, facilities, management? New products (Miraito cancer, new medical in Japan); new reinsurance platform (Bermuda); continued investment in U.S. group/consumer-direct channels. Management continuity intact (Amos as Chairman/CEO; Max Broden CFO; Virgil Miller President/U.S.).

APPENDIX B — Source Appendix

Aflac Incorporated (NYSE: AFL) — Research as of 2026-06-27

All material facts in this article trace to the sources below. Primary sources (SEC filings, the company’s own disclosures) are prioritized; third-party aggregators are used for cross-checks and own-history valuation context and are reconciled to filings. Where an aggregator conflicts with a filing, the filing governs (and the discrepancy is flagged).

Primary — SEC filings (EDGAR, CIK 0000004977)

1. Aflac Incorporated Form 10-K for FY2025 (afl-20251231; filed 2026-02-25). Source of: total shareholders’ equity $29,490M; book value per share ~$56.85; GAAP ROE 13.1%; adjusted book value (ex-AOCI) $28.0bn / $54.06 per share; segment pretax adjusted earnings (Japan $3,440M, U.S. $1,421M, Corporate $101M; total $4,962M for 2025, $4,945M 2024, $4,310M 2023); net earnings $3,646M / diluted EPS $6.82; total revenues down ~9%; weighted-average yen/dollar rates 149.32 (2025) / 150.97 (2024) / 140.57 (2023); buyback volumes (33.0M shares / ~$3.5bn 2025; 30.4M / $2.8bn 2024); 100M-share repurchase authorization.
2. Trailing 60-month SEC corpus (public filings): FY2021–FY2025 10-Ks, 15 10-Qs, 40 8-Ks, DEF 14A/DEFA14A, Form 3/4/5 (insider filings listed). Used for the multi-year financial trend, the 8-K event timeline, and the capital-return history.
3. DEF 14A (proxy) — historical, used for incentive-compensation design (adjusted EPS and adjusted ROE ex-FX / AROE metrics; RBC/solvency). Open item: most-recent proxy needed to confirm current ownership and comp design.

Primary — company disclosures

4. Aflac Incorporated Q1 2026 earnings call transcript (2026-04-30; public earnings-call transcript). Source of: Q1-26 net EPS $1.98 / adjusted EPS $1.75 ($1.77 ex-FX, +6.6% YoY); adjusted ROE 12.8% (16.4% ex-FX); Japan sales +25.5%, benefit ratio 62.9%, pretax margin 35%, persistency 92.8%, underlying earned premium −1.3%; U.S. sales +2.9%, net earned premium +3.5%, benefit ratio 47.2%, pretax margin 20.4%, persistency 79.3%, group/voluntary +12.4%; capital (ESR 227% / 243% with USP; combined RBC ~560%; holdco liquidity $3.4bn; adjusted leverage 21.2%; ~65% yen debt); the ~¥90bn lapse hurdle vs ~¥74–80bn sales guide; Aflac Re Bermuda / Japan Post reinsurance; CRE/loan impairments ($24M REO, $19M charge-offs); 43 consecutive years of dividend increases; $1.3bn returned in Q1 ($1.0bn buyback + $0.315bn dividends).

Secondary / third-party (cross-check; reconciled to filings)

5. Public aggregated financial data — income statement, balance sheet, cash flow, per-share and profitability ratios, valuation multiples (2020–2025). Used for the multi-year trend and share-count history. Flagged data error: ROIC’s per-share book value (~$103) and resulting ROE (~6.8%) and P/B (~1.07x) for AFL are doubled/garbled; the memo uses the 10-K equity of $29,490M (true BVPS ~$56.85, ROE 13.1%) instead. ROIC’s enterprise-value figures for AFL are also non-meaningful (deeply negative) and were not used.
6. AZI own-history valuation index (2026-06-26): composite percentile 94.49th; P/B 2.76x (99.98th), P/E 13.71x ttm (86.97th), P/S 3.49x (96.52nd); latest price $120.15, ttm EPS $8.76, BVPS $43.59 (AZI’s book definition runs lower than the 10-K’s stated equity; the memo cross-checks against the filing). Used strictly for own-history valuation context, never cross-sectionally.
7. AZI 5-year price history (CSV) — daily adjusted/unadjusted OHLCV, beta 0.36, EMAs. Source of the price event map: ~$43 (Jan 2021) → $120.15 (2026-06-26, all-time high); year-end closes $58.39 / $71.94 / $82.50 / $103.44 / $110.27 (2021–2025); 52-week low $98.09 (Aug 2025).
8. AZI news feed (2026-06-26): 7 articles, predominantly minor/neutral (Zacks industry pieces, 5-year-return retrospectives, defensive-trade commentary) — a quiet tape, consistent with a low-volatility defensive name.
9. FactorsToday factor/risk model (2026-06-26): primary factor loadings on Industry-Insurance (beta ~0.68) and LowVolatility (~0.58), Market (~0.50); stock beta 0.36, positive alpha; risk-adjusted track record (y3 return +23.8% ann, y3 Sharpe 1.11, y3 max drawdown −13.5%; lifetime max drawdown −82.7%; m3 return +66% ann reflecting a strong recent quarter). Used for the positioning/momentum read (a crowded low-vol long at highs). Third-party statistical estimates — facts (loadings, drawdowns) reportable; “continue/revert” is interpretation.

Notes on authority and reconciliation

• For a U.S. filer, EDGAR and the 10-K/10-Q are primary; ROIC/AZI/FactorsToday accelerate and cross-check but do not replace the filing.
• The most material reconciliation in this report is book value / ROE: the 10-K figure ($29,490M equity; $56.85 BVPS; 13.1% ROE) governs over ROIC’s erroneous doubled-book figures, and the adjusted-book lens ($54.06/share ex-AOCI) is used to temper the raw 99.98th-percentile P/B optic.
• No price target or recommendation appears in the memo body; the single labeled subjective view is in the Author’s Take.